AAIPharma Services provides pharma and biotech companies with drug product development and contract manufacturing services. Our clients may select specific services or a complete development package.
ARVYS Proteins excels in protein purification from recombinant and natural sources, assay development and performance, protein characterization, cell culture, genetic engineering and recombinant protein expression.
Micromeritics Pharmaceutical Services is a contract service provider, providing a broad range of analytical, development, and consulting services to the pharmaceutical industry.
Agilent Technologies Inc. introduced its monolithic laser combiner system for confocal and fluorescence microscopy applications.
PharmaDiagnostics NV announces the launch of SoPRano, a high-performance set of screening tools to accelerate the drug discovery process for pharmaceutical and biotechnology companies.
Abbott has completed its $123 million acquisition of STARLIMS Technologies Ltd., a leader in laboratory information management systems.
Aureus Pharma announces its participation in the Biointelligence R&D program, designed to promote the use of systemic modeling and simulation tools to exploit biomedical databases to improve research efficiency.
Allon Therapeutics Inc. announced that a Phase 1 clinical trial of its lead neuroprotective drug, davunetide, which began patient enrolment January 28, 2010, has been completed.
Biogen Idec and Elan Corporation, plc announced enrollment of the first patient in a global Phase 3b, randomized, rater-blinded, active-controlled study designed to evaluate switching to TYSABRI from Copaxone or Rebif in patients with relapsing remitting multiple sclerosis.
By enhancing the activity of immune cells that protect against runaway inflammation, researchers at NYU Langone Medical Center may have found a novel therapy for rheumatoid arthritis and other autoimmune diseases.
Canadian researchers have discovered a previously hidden channel to attack leukemia and other cancer cells, according to a new study published in the Journal of Biological Chemistry.
Like a skittish driver slamming the brakes, a special class of T cells may be limiting the effectiveness of therapeutic vaccines for HIV by slowing the immune system response too soon, report University of Pittsburgh health science researchers in the current issue of PLoS ONE.
Millions of patients with high blood pressure and heart failure take a class of drugs known as ACE (angiotensin-converting enzyme) inhibitors. These drugs prevent the body from processing angiotensin II, a hormone that constricts blood vessels.
GlaxoSmithKline and Pfizer Inc. made a 10-year commitment to supply developing nations with new pneumonia vaccines, the Geneva-based public-private partnership GAVI Alliance said.
A federal jury has found that Pfizer Inc. violated anti-racketeering laws in promoting its epilepsy drug Neurontin for unapproved uses and must pay at least $142 million in damages.